Virus sequences show a SARS-COV-2 mutation has taken over in new Houston COVID-19 cases: MedRxiv. This could impair vaccine efforts if it happens repeatedly.

A preprint published on MedRxiv dated September 22, 2020 revealed that a mutation in SARS-COV-2 RNA has taken over in Houston (and probably many other areas) based on sequencing of over 5,000 cases. The mutation causes the replacement of a single amino acid at location 614 in the spike protein. It is known as D614G (arginine –D– replaced by glycine –G.)

This mutation was discovered in February and was followed in the United Kingdom (UK) with sequencing of over 25,000 cases there. A paper discussing this sequence database was published in MedRxiv on September 1, 2020. The findings of that paper agree with the Houston paper in all important respects but the new paper adds more information.

The mutation produces viral particles with many more spikes on their surfaces. It is these spikes that the virus uses to attach to host cells by grabbing on to their angiotensin-converting enzyme 2 (ACE-2) receptors. ACE-2 receptors are present on the outer membranes of most endothelial cells (those that line the inside surfaces of the nose, throat, eye conjunctiva, and gastrointestinal tract as well as inside blood vessels.)

This mutation increases infectiousness but not lethality. Initial viral loads were increased in the nasopharynxes (noses and throats) of patients infected with the mutated virus, but these patients were no more likely to have severe disease. This mutation has taken over, outcompeting the previous version of the virus by spreading more easily.

The fact that infections with this mutation are no more severe is logical when we consider that making the patient sicker doesn’t help the virus spread– killing the patient isn’t good for the virus.

The sequencing of so many separate viruses has revealed numerous mutations, many of which were seen in only a few cases. The authors of the paper advocate for virus sequences from many more patients to help us monitor the spread of the virus and trace contacts.

Another reason to sequence more viruses is that some mutations will reduce the ability of antibodies to neutralize the virus. In fact, the authors found that monoclonal antibody CR30022 was less able to recognize some mutations. This could be a factor in patients who have repeated infections with different strains of the virus.

This may also impair the ability of manufactured monoclonal antibodies to treat the disease in new cases. Monoclonal antibodies are being actively studied as a treatment for COVID-19, but the fact that they have to be separated and manufactured (which takes several months) may make them too late to be helpful in some new cases.

Mutations could also affect the ability of vaccines to provide protection against the virus. If this happens repeatedly, we could find ourselves in the same position as we are with influenza: we will need new immunizations on a yearly basis.